Bayer wins US legal victory against Roundup cancer claims; shares surge
Adds discussion of potential Supreme Court appeals in paragraphs 11-12
By Jonathan Stempel
Aug 16 (Reuters) -Bayer BAYGn.DE won a legal victory in its fight to limit liability from claims its Roundup weed killer causes cancer, as a U.S. appeals court said on Thursday that federal law shields the German company from a lawsuit by a Pennsylvania landscaper.
Shares of Bayer rose as much as 13.2% in Friday trading in Germany, on optimism the decision could eliminate much of its remaining legal liabilities for Roundup, made by its Monsanto unit.
The 3rd U.S. Circuit Court of Appeals in Philadelphia rejected plaintiff David Schaffner's claim that Monsanto violated state law by failing to put a cancer warning on the label for Roundup.
Schaffner was diagnosed in 2006 with a kind of cancer called non-Hodgkin's lymphoma, a common claim for Roundup plaintiffs.
He and his wife Theresa sued Bayer in 2019, partly over how his illness affected their relationship.
Chief Judge Michael Chagares wrote for a unanimous three-judge panel that the Federal Insecticide, Fungicide, and Rodenticide Act requires nationwide uniformity in pesticide labels, and prevented Pennsylvania from adding a cancer warning.
COURTS ARE DIVIDED
The decision conflicts with rulings from federal appeals courts in San Francisco and Atlanta in similar cases.
That raises the prospect the U.S. Supreme Court could resolve the split if the Schaffners appealed, perhaps as soon as next year. The court is not required to hear an appeal, but often accepts cases when lower courts disagree on the law.
Chip Becker, a lawyer for the Schaffners, said his clients were disappointed with the decision and were reviewing their legal options, and that federal law should not preempt their failure-to-warn claim.
In a research note, Barclays analysts said "this ruling was not expected," and Bayer believed a positive Supreme Court resolution "could bring glyphosate litigation to an end."
The Supreme Court declined to hear Bayer's appeal from the San Francisco decision. Bayer has until Sept. 5 to appeal the Atlanta decision, court records show.
Bayer said it was pleased with Thursday's decision and looked forward to presenting its arguments to the Supreme Court, saying that court should "settle this important issue of law."
The German company has long maintained that Roundup and its active ingredient glyphosate are safe.
SHARE SLUMP
Bayer has faced extensive litigation over Roundup, and through Thursday had seen its share price fall more than 73% since buying Monsanto for $63 billion in June 2018.
It settled much of the litigation for $10.9 billion in 2020, but still faces about 58,000 claims. Another 114,000 claims have been settled or rejected.
Though Bayer won 14 of 23 Roundup trials through July 23, one victory was overturned on appeal, and the losses saddled it with billions of dollars of damages awards.
The Schaffners settled with Bayer in September 2022, conditioned on Bayer being unable to convince courts that federal law preempted Pennsylvania's cancer warning.
Chagares said it did, and that this approach "best achieves Congress's stated aim of uniformity in pesticide labeling."
Roundup is among the most widely used weed killers in the United States. Bayer phased out sales for home use last year.
The case is Schaffner et al v Monsanto Corp, 3rd U.S. Circuit Court of Appeals, No. 22-3075.
Reporting by Jonathan Stempel in New York
Additional reporting by Brendan Pierson and Ludwig Burger
Editing by Jonathan Oatis and Frances Kerry
Ativos relacionados
Últimas notícias
Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.
Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.
Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.